SFDA Releases Version 3.0 of Verification & Abridged Pathways Guideline

RIAR Consulting is pleased to share an important regulatory update from the Saudi Food & Drug Authority (SFDA) that will significantly impact pharmaceutical product registration and lifecycle management in Saudi Arabia.

The SFDA has officially released Version 3.0 of the Verification & Abridged Pathways Guideline, reinforcing its commitment to regulatory modernization, international alignment, and accelerated patient access to safe and effective medicines in the Kingdom (effective January 2026).

Official SFDA guideline: Verification & Abridged Pathways – SFDA

Key Highlights of the Update

The revised guideline introduces several critical changes that industry stakeholders should carefully note:

• Expanded Application Scope
• Updated Definition of “Sameness of Product”
• Clearer Variation Requirements
• Revised Documentation & Formats

Expanded Application Scope

The verification and abridged pathways now cover both registration and variation applications, providing greater flexibility across the entire product lifecycle.

Updated Definition of “Sameness of Product”

The SFDA has refined the definition to better align with reference regulatory authorities, improving clarity and harmonization with global standards.

Clearer Variation Requirements

Enhanced guidance has been introduced for variation submissions, enabling smoother regulatory interactions and predictable lifecycle management.

Revised Documentation & Formats

Updated application formats and documentation requirements aim to streamline submissions and reduce regulatory complexity.

Why This Matters

This update represents a significant step toward improving regulatory efficiency and transparency in Saudi Arabia. By aligning more closely with international regulatory frameworks, the SFDA continues to strengthen the Kingdom’s position as a progressive and attractive pharmaceutical market.

For global and regional manufacturers, early understanding and strategic adaptation to these changes will be essential for:

• Faster market entry
• Efficient lifecycle management
• Sustained regulatory compliance

How RIAR Consulting Can Support You

RIAR Consulting actively monitors SFDA regulatory developments and supports companies with:

• Verification & abridged pathway strategy
• Registration and variation submissions
• Gap assessments and dossier readiness
• End-to-end SFDA regulatory compliance

Stay connected with RIAR Consulting as we continue to break down regulatory changes and share practical guidance to help you navigate the evolving SFDA landscape effectively.